The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Ultragenyx Pharmaceutical Inc.

27-2546083

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)  ☐        (b)  ☐

SEC USE ONLY

SOURCE OF FUNDS (See Instructions)

WC

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(D) OR 2(E)

☐

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

SOLE VOTING POWER

2,200,000

SHARED VOTING POWER

0

SOLE DISPOSITIVE POWER

2,200,000

SHARED DISPOSITIVE POWER

0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,200,000

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

☐

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

9.0%*

TYPE OF REPORTING PERSON (See Instructions)

CO

This percentage is calculated based upon 24,493,084 outstanding shares of common stock, par value $0.001 per share, of the Issuer (the “Common Stock”) as of November 2, 2020 disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the “Form 10-Q”) filed with the Securities and Exchange Commission (“SEC”) on November 9, 2020.

Purpose of Transaction

Interest in Securities of the Issuer

As of the date hereof, the Reporting Person beneficially owns an aggregate of 2,200,000 shares of Common Stock, which represents 9.0% of the outstanding Common Stock as of November 2, 2020 based on the information disclosed by the Issuer in the Form 10-Q filed with the SEC on November 9, 2020. As of the date hereof, in accordance with the Issuer’s director compensation policy, the Issuer has granted to Karah Parschauer, the Executive Vice President and General Counsel of the Reporting Person and a director of the Issuer, options to purchase 50,000 shares of Common Stock, of which 41,250 are exercisable within 60 days of the date hereof, for her service as a director of the Issuer. As long as Ms. Parschauer remains a director of the Issuer, it is anticipated that she will continue to receive equity grants in accordance with the Issuer’s director compensation policy. Except as described in this Item 5, neither the Reporting Person nor, to the knowledge of the Reporting Person, any of the other persons listed on Schedule I hereto beneficially owns any other securities of the Issuer.

As of the date hereof, the Reporting Person has the sole power to vote or direct the vote and sole power to dispose or to direct the disposition of 2,200,000 shares of Common Stock.

Reference is Item 4 above. Except as set forth herein, neither the Reporting Person nor, to the knowledge of the Reporting Person, any of the other persons listed on Schedule I hereto has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock covered by this Schedule 13D.

Not applicable.

Name

Principal Occupation

Citizenship